Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.
Escient Pharmaceuticals has raised $120.0M in total funding. The most recent round was Series C. The last funding was announced in November 2022.
Escient Pharmaceuticals's investors include New Enterprise Associates, Redmile Group, Perceptive Advisors, Sanofi Ventures, The Column Group.
Escient Pharmaceuticals is headquartered in San Diego, United States.
Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.
Escient Pharmaceuticals is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Escient Pharmaceuticals — Funding & Investors." VCBacked, November 28, 2022, https://www.vcbacked.co/company/escient-pharmaceuticals. Accessed July 31, 2026.
VCBacked. (2022). Escient Pharmaceuticals — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/escient-pharmaceuticals
{{cite web |title=Escient Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/escient-pharmaceuticals |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated